Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements

This article was originally published in The Tan Sheet

Executive Summary

Manufacturers of nonprescription drugs and dietary supplements will have to provide company contact information on product labels in order for consumers to report serious adverse events associated with the products under long-awaited legislation introduced June 21

You may also be interested in...



Supplement Adverse Event Reports Grow, But FDA Says 'Serious' Intel Is Short

Serious AERs submitted to FDA have plateaued since 2010, though reports the agency receives from consumers steadily increased. While FDA suspects supplement firms are not providing all serious AERs as required, stakeholders say the agency overestimates the number of serious AERs.

AER Bills Likely To See Action In November Lame Duck Session

Both the House and the Senate versions of the Adverse Event Reporting bill may be acted on in the week after November elections, according to the United Natural Products Alliance

AER Bills Likely To See Action In November Lame Duck Session

Both the House and the Senate versions of the Adverse Event Reporting bill may be acted on in the week after November elections, according to the United Natural Products Alliance

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel